JP2015526434A - ペプチド−デンドリマーコンジュゲート及びその使用 - Google Patents

ペプチド−デンドリマーコンジュゲート及びその使用 Download PDF

Info

Publication number
JP2015526434A
JP2015526434A JP2015526845A JP2015526845A JP2015526434A JP 2015526434 A JP2015526434 A JP 2015526434A JP 2015526845 A JP2015526845 A JP 2015526845A JP 2015526845 A JP2015526845 A JP 2015526845A JP 2015526434 A JP2015526434 A JP 2015526434A
Authority
JP
Japan
Prior art keywords
compound
dendrimer
agent
linker
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015526845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526434A5 (https=
Inventor
デミュール，ミシェル
ラロック，アラン
ヤン，ガオチエン
トリパシー，サスミタ
Original Assignee
アンジオケム インコーポレーテッド
アンジオケム インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジオケム インコーポレーテッド, アンジオケム インコーポレーテッド filed Critical アンジオケム インコーポレーテッド
Publication of JP2015526434A publication Critical patent/JP2015526434A/ja
Publication of JP2015526434A5 publication Critical patent/JP2015526434A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015526845A 2012-08-14 2013-08-14 ペプチド−デンドリマーコンジュゲート及びその使用 Pending JP2015526434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682991P 2012-08-14 2012-08-14
US61/682,991 2012-08-14
PCT/CA2013/050621 WO2014026283A1 (en) 2012-08-14 2013-08-14 Peptide-dendrimer conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2015526434A true JP2015526434A (ja) 2015-09-10
JP2015526434A5 JP2015526434A5 (https=) 2016-10-06

Family

ID=50101156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015526845A Pending JP2015526434A (ja) 2012-08-14 2013-08-14 ペプチド−デンドリマーコンジュゲート及びその使用

Country Status (7)

Country Link
US (1) US9687561B2 (https=)
EP (1) EP2885318A4 (https=)
JP (1) JP2015526434A (https=)
CN (1) CN104781276A (https=)
AU (1) AU2013302270A1 (https=)
CA (1) CA2881602A1 (https=)
WO (1) WO2014026283A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531962A (ja) * 2015-10-29 2018-11-01 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用
JPWO2024029242A1 (https=) * 2022-08-05 2024-02-08

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
WO2016090495A1 (en) * 2014-12-11 2016-06-16 Angiochem Inc. TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF
ES2965764T3 (es) 2015-02-24 2024-04-16 Hope City Plataformas de cribado de bibliotecas abordadas espacialmente codificadas químicamente
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
WO2017048789A1 (en) * 2015-09-14 2017-03-23 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
CN106854231B (zh) * 2015-12-09 2020-08-11 中国科学院大连化学物理研究所 一种硫巯化多肽的富集方法
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
PL417159A1 (pl) * 2016-05-11 2017-11-20 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
PL3458074T3 (pl) * 2016-05-16 2024-11-12 Board Of Regents Of The University Of Texas System KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
CN106279635B (zh) * 2016-08-10 2019-01-25 同济大学 类抗菌肽和囊泡及其制备方法和应用
ES2677242B1 (es) * 2017-01-31 2019-03-27 Univ Alcala Henares Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
WO2020051223A1 (en) 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
EP3846857A4 (en) 2018-09-04 2022-10-12 The Board Of Regents Of The University Of Texas System COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
WO2020113036A2 (en) * 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
CN110170055A (zh) * 2019-06-04 2019-08-27 哈尔滨理工大学 一种新型双重脑缺血靶向纳米载体材料的制备方法
WO2021046307A1 (en) * 2019-09-04 2021-03-11 North Carolina State University Hybridized poly(amidoamine)-amino acid dendrimers
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
WO2021207020A1 (en) * 2020-04-06 2021-10-14 Tiba Biotech Llc Carriers for efficient nucleic acid delivery
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN117363697A (zh) * 2023-10-10 2024-01-09 上海烈冰生物医药科技有限公司 一种用于核酸捕获的高密度探针磁珠制备方法
WO2025096681A1 (en) 2023-10-31 2025-05-08 Tiba Biotech Llc Novel gene delivery agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510829A (ja) * 2004-08-25 2008-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン デンドリマーに基づく組成物およびそれらの使用法
JP2008515975A (ja) * 2004-10-13 2008-05-15 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗癌化合物および方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
KR19990008458A (ko) 1995-05-08 1999-01-25 쉬어러 피터 알. 쿠니츠(kunitz) 타입 프로테아제 억제 물질
WO1996039183A1 (en) 1995-05-31 1996-12-12 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector molecules
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
AU6682598A (en) 1997-03-04 1998-09-22 Bio-Technology General Corporation Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
CN1263473A (zh) 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
AU2002347910A1 (en) 2001-10-16 2003-04-28 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
AU2003209577A1 (en) 2002-02-07 2003-09-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
KR20060036476A (ko) 2003-08-08 2006-04-28 가부시키가이샤 티슈 타겟팅 쟈판 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
CA2615617A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
JP2010506860A (ja) 2006-10-19 2010-03-04 アンジオケム，インコーポレーテッド Ｐ−糖タンパク質機能を刺激するための化合物およびその使用
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2008255556B2 (en) 2007-05-29 2014-08-07 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0821310A2 (pt) 2007-12-20 2015-06-16 Angiochem Inc Conjugados polipeptídeos-ácido nucleico e usos dos mesmos
MX355683B (es) 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2370472A4 (en) 2008-12-05 2013-04-24 Angiochem Inc LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
US20110318322A1 (en) 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
CN103819564A (zh) 2009-06-11 2014-05-28 安吉奥开米公司 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
EP3000481A3 (en) 2009-07-14 2016-05-11 Mayo Foundation for Medical Education and Research Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier
AU2010305284A1 (en) 2009-10-06 2012-05-03 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
WO2011153642A1 (en) 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
JP2013530993A (ja) * 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
WO2012037687A1 (en) * 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
WO2013056096A1 (en) 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
CN104145015A (zh) 2011-12-01 2014-11-12 安吉奥开米公司 靶向的溶酶体酶化合物
BR112014013250A2 (pt) 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima alvo e usos dos mesmos
AU2013273894A1 (en) 2012-06-15 2015-02-05 Angiochem Inc. Targeted iduronidase compounds
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
US20160106856A1 (en) 2012-08-14 2016-04-21 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
JP2015535523A (ja) 2012-11-12 2015-12-14 アンジオケム インコーポレーテッド アプロチニン由来ポリペプチド−抗体コンジュゲート
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
JP2015536658A (ja) 2012-11-30 2015-12-24 アンジオケム インコーポレーテッド 標的化イズロン酸−２−スルファターゼ化合物
WO2014194428A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds
WO2014194429A1 (en) 2013-06-06 2014-12-11 Angiochem Inc. Targeted enzyme compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510829A (ja) * 2004-08-25 2008-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン デンドリマーに基づく組成物およびそれらの使用法
JP2008515975A (ja) * 2004-10-13 2008-05-15 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗癌化合物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOMATERIALS, vol. 32, JPN6017025156, 2011, pages 6832 - 6838, ISSN: 0003852126 *
CHEMICAL COMMUNICATIONS, vol. 47, JPN6017025157, 2011, pages 8130 - 8132, ISSN: 0003852127 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531962A (ja) * 2015-10-29 2018-11-01 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用
JP7108306B2 (ja) 2015-10-29 2022-07-28 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用
JPWO2024029242A1 (https=) * 2022-08-05 2024-02-08
WO2024029242A1 (ja) * 2022-08-05 2024-02-08 一丸ファルコス株式会社 新規ｌｒｐ１結合ペプチド
JP7665261B2 (ja) 2022-08-05 2025-04-21 一丸ファルコス株式会社 新規ｌｒｐ１結合ペプチド

Also Published As

Publication number Publication date
AU2013302270A1 (en) 2015-03-26
US9687561B2 (en) 2017-06-27
CA2881602A1 (en) 2014-02-20
EP2885318A4 (en) 2016-03-30
EP2885318A1 (en) 2015-06-24
US20160015823A1 (en) 2016-01-21
CN104781276A (zh) 2015-07-15
WO2014026283A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
JP2015526434A (ja) ペプチド−デンドリマーコンジュゲート及びその使用
JP7564143B2 (ja) Ｘｔｅｎ共役組成物およびそれを製造する方法
CN104684576B (zh) 聚乙二醇化的oxm变体
EP2928502B1 (en) Conjugates of proteins and multivalent cell-penetrating peptides and their uses
US20170326233A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
US20170281787A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
ES2855169T3 (es) Conjugados de polipéptido-anticuerpo derivados de aprotinina
JP2004533414A5 (https=)
AU4094300A (en) Amplification of folate-mediated targeting to tumor cells using polymers
WO2013056096A1 (en) Polypeptide-opioid conjugates and uses thereof
CN103080125A (zh) 用于治疗性结合物的短且含d氨基酸的多肽及其使用
US20200157151A1 (en) Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
TW202317604A (zh) 用於治療遺傳性血鐵沉積症之鐵調素模擬物
ES2228082T3 (es) Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados.
CN106163569A (zh) 活化的神经降压素分子及其用途
JP2021536499A (ja) 血液脳関門を通過することができるポリペプチド
US20240052005A1 (en) Improved cell-penetrating peptides and fusion proteins
CN120225216A (zh) 包含莰醇和肽的缀合物及其用途
BR112014021256B1 (pt) Composições de conjugado de xten e métodos de produção das mesmas
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807